| http://www.w3.org/ns/prov#value | - There is no mention of agranulocytosis anywhere in the document, including the section on reported adverse events.> > FDA Psychopharmacologic Drugs Advisory Committee Meeting> > http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf> > It is actually remarkable that agranulocytosis didn't appear just by chance in the
|
